Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors
Human Gene Therapy · 01.05.2024 · 35 (9-10) · 355-364
DOI: 10.1089/hum.2023.225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, erschienen am 01.05.2024. Verfasst von Rebecca Xicluna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, CHU de Nantes, INSERM, TaRGeT - Translational Research in Gene Therapy, UMR 1089, Nantes, France. Hauptthemen laut MEDLINE: Dependovirus, Capsid Proteins, Immunity, Cellular, Genetic Vectors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nantes Université, CHU de Nantes, INSERM, TaRGeT - Translational Research in Gene Therapy, UMR 1089, Nantes, France.
ORCID-Profile: Gwladys Gernoux
Zitieren
APA
Xicluna, R., Avenel, A., Vandamme, C., Devaux, M., Jaulin, N., Couzinié, C., Le Duff, J., Charrier, A., Guilbaud, M., Adjali, O., & Gernoux, G. (2024). Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors. Human Gene Therapy, 35(9-10), 355-364. https://doi.org/10.1089/hum.2023.225
Vancouver
Xicluna R, Avenel A, Vandamme C, Devaux M, Jaulin N, Couzinié C, et al. Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors. Human Gene Therapy. 2024;35(9-10):355-364. doi:10.1089/hum.2023.225
BibTeX
@article{Xicluna2024,
author = {Xicluna, Rebecca and Avenel, Allan and Vandamme, Céline and Devaux, Marie and Jaulin, Nicolas and Couzinié, Célia and Le Duff, Johanne and Charrier, Alicia and Guilbaud, Mickaël and Adjali, Oumeya and Gernoux, Gwladys},
title = {Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors},
journal = {Human Gene Therapy},
year = {2024},
volume = {35},
number = {9-10},
pages = {355--364},
doi = {10.1089/hum.2023.225}
}
EUVIMED